SASY.PA
現在値
95.09EUR変化
0.21(+0.22%)出来高
54,385本日のレンジ
-
95.8852週レンジ
-
105.18∙ 約20分前の相場を表示しています。
May 25 (Reuters) - Sanofi SA <SASY.PA>::PRESS RELEASE: ANNUAL GENERAL MEETING OF MAY 25, 2023 – FRÉDÉRIC OUDÉA NEW CHAIRMAN OF THE BOARD OF DIRECTORS.BOARD COMPOSITION: FRÉDÉRIC OUDÉA BECOMES INDEPENDENT DIRECTOR AND CHAIRMAN OF BOARD.
May 18 (Reuters) - Sanofi SA <SASY.PA>::UNITED STATES SUPREME COURT'S RULING IN AMGEN V. SANOFI ET. AL..SAYS DECISION UNANIMOUSLY AFFIRMS THE UNITED STATES FEDERAL CIRCUIT COURT'S OPINION THAT IS FAVORABLE TO SANOFI AND REGENERON <<<REGN.O>>>.SAYS UNITED STATES FEDERAL CIRCUIT COURT'S OPINION THAT AMGEN'S ASSERTED U.S. PCSK9 PATENT CLAIMS ARE INVALID.
May 12 (Reuters) - Sanofi SA <SASY.PA>::NIRSEVIMAB DELIVERS 83% REDUCTION IN RSV INFANT HOSPITALIZATIONS IN A REAL-WORLD CLINICAL TRIAL SETTING.HARMONIE PHASE 3B DATA REINFORCE NIRSEVIMAB'S CONSISTENT AND HIGH EFFICACY AGAINST INFANT HOSPITALIZATIONS DUE TO RSV.DATA PRESENTED AT ESPID ADD TO BODY OF EVIDENCE DEMONSTRATING NIRSEVIMAB'S PROTECTION AGAINST RSV-RELATED LOWER RESPIRATORY TRACT DISEASE (LRTD) AND CONFIRM ITS FAVORABLE SAFETY PROFILE IN MULTI-COUNTRY, REAL-WORLD CONDITIONS.THROUGHOUT HARMONIE, NIRSEVIMAB MAINTAINED A FAVORABLE SAFETY PROFILE, CONSISTENT WITH PIVOTAL TRIAL RESULTS.TRIAL RECRUITED MORE THAN 8,000 INFANTS AND TOOK PLACE AT NEARLY 250 SITES ACROSS FRANCE, GERMANY AND UNITED KINGDOM.
May 10 (Reuters) - Sanofi SA <SASY.PA>::VEEVA PARTNERS WITH SANOFI TO TRANSFORM ITS QUALITY SYSTEM.
May 4 (Reuters) - Sanofi SA <SASY.PA>::DUPIXENT® (DUPILUMAB INJECTION) IS NOW APPROVED IN CANADA FOR TREATMENT OF ADULT AND ADOLESCENT PATIENTS (12+) WITH EOSINOPHILIC ESOPHAGITIS.
May 2 (Reuters) - Maze Therapeutics: :ANNOUNCED ON MONDAY EXCLUSIVE WORLDWIDE LICENSE AGREEMENT WITH SANOFI SA FOR MZE001, AN ORAL SUBSTRATE REDUCTION THERAPY FOR THE TREATMENT OF POMPE DISEASE .
April 27 (Reuters) - Sanofi SA <SASY.PA>::SANOFI COMPLETES ACQUISITION OF PROVENTION BIO, INC..
April 17 (Reuters) - Sanofi SA <SASY.PA>::ELISABETH MORENO JOINS SANOFI'S DIVERSITY, EQUITY AND INCLUSION COUNCIL.NAMES EX FRENCH GOVERNMENT MINISTER ELISABETH MORENO TO ITS DIVERSITY BOARD.APPOINTMENT OF ELISABETH MORENO FOR THE NEXT THREE YEARS.
April 11 (Reuters) - Sanofi <SASY.PA>::Modification of existing collaboration agreement with AstraZeneca gives Sanofi full commercial control of nirsevimab and enhanced agility in the U.S..Existing collaboration agreement with AstraZeneca remains in place for nirsevimab activities ex-U.S..SOBI WILL TERMINATE ITS PARTICIPATION AGREEMENT WITH ASTRAZENECA, AND SANOFI AND ASTRAZENECA WILL UPDATE COLLABORATION AGREEMENT SO THAT SANOFI HAS FULL COMMERCIAL CONTROL OF NIRSEVIMAB IN U.S..WITH RESPECT TO TERRITORIES OUTSIDE U.S., EXISTING COLLABORATION AGREEMENT BETWEEN ASTRAZENECA AND SANOFI CONTINUES TO GOVERN THAT RELATIONSHIP..NEW AND UPDATED CONTRACTUAL AGREEMENTS DO NOT IMPACT NIRSEVIMAB REGISTRATION AND LAUNCH IN U.S.ALL PARTIES REMAIN COMMITTED TO MAKING BEYFORTUS AVAILABLE FOR ALL INFANTS IN TIME FOR 2023/24 RSV SEASON.
April 10 (Reuters) - Sanofi SA <SASY.PA>::PRESS RELEASE: SANOFI ANNOUNCES WITHDRAWAL AND REFILING OF PREMERGER NOTIFICATION AND REPORT FORM UNDER THE HART-SCOTT-RODINO ACT AND EXTENSION OF TENDER OFFER TO ACQUIRE PROVENTION BIO, INC..SANOFI - HAS ELECTED TO WITHDRAW AND REFILE ITS PREMERGER NOTIFICATION AND REPORT FORM TO PROVIDE FTC WITH ADDITIONAL TIME FOR REVIEW.SANOFI - FOLLOWING REFILING, WAITING PERIOD UNDER HART-SCOTT-RODINO ACT WILL EXPIRE AT 11:59 P.M., EASTERN TIME, ON APRIL 25, 2023.
金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。